# PhorMed

Join Us in the Fight to Cure Cancer! Pre-Public Limited Time Offer *10% Bonus Discount*



- Canonical URL: https://wefunder.com/phormed
- Entity ID: wefunder:company:149371
- Last updated: 2026-06-06T05:02:11Z
- Generated at: 2026-06-06T14:01:09Z

## Quick facts
- In a clinical study, we helped 83% of patients beat cancer
- Our drug repairs damaged cells and kills cancer
- On a mission to bring new hope and a brighter future to patients battling life-threatening diseases
- $3.5 million raised from >4,100 investors: Crowdfunding and Angel investors
- Undervalued position, potential to buy low/sell high. PhorMed = $53M; Similar Companies = $290M-1.2B
- FDA allowing “FAST-TRACKING” clinical studies = huge time & cost savings
- Our team has 533 peer-reviewed publications
- Company is ready to start three phase 2 studies

## Active fundraises
- wefunder:fundraise:105392: 4(a)(6) successful (USD)
- wefunder:fundraise:105391: 4(a)(6) successful (USD)

## Story
The company anticipates a clear path toward an open and ever-growing marketplace. Our planned GO-PUBLIC transaction offers our investors an exit strategyWe save lives by treating life-threatening diseases, repairing damaged cells, killing cancer cells to destroy cancer at its coreOur *platform drug reverses disease utilizing cell repair therapy to target damaged and mutated cells, having the ability to fix various cell types and kill cancer cells. Additionally, our drug boosts the immune system’s ability to fight cancer, an activity called immunotherapy. The drug is administered through intravenous infusions (I.V. drip).*Platform is defined as one drug applied across many applications.Many common life-threatening diseases have few to no treatment options or require dangerous treatments with long-lasting side effectsMany patients are often faced with the harsh reality of either no viable treatment options or, in cases like cancer, having to endure harmful and painful treatments with severe, long-lasting, and possible organ-damaging side effects. These harsh treatments can increase the already high chance of relapse. In some cases, severe side effects show up years after treatment.Our platform drug shows unparalleled promise in curing cancer and various other deadly diseases, giving patients the opportunity to reclaim their health and live fuller livesWe are currently in clinical trials, advancing the development of our platform drug, RP-323. This treatment targets life-threatening diseases, including Acute Myeloid Leukemia (AML) and Hodgkin’s Lymphoma (cancer) in patients with relapsed/refractory disease, meaning their cancer resisted treatment or came back after first getting better, as well as Parkinson’s disease (brain disorder) and Acute Respiratory Distress Syndrome (ARDS/Lung disorder).Our technology is a targeted therapy that can repair a variety of damaged and mutated cells while killing cancer cells to directly attack cancer at its root.(Watch the Video Below!)While we actively work on our go-public transaction, we continue to evaluate partnership opportunities for ongoing R&D and future distribution, allocating funds in the most efficient manner to achieve our primary goal: clinical success and saving lives.Our cell repair therapy:• Helped 83% of our AML patients beat cancer• Delivers significant tumor reduction in Hodgkin's Lymphoma• Reduces lung inflammation, a key driver of ARDS, helping patients breathe again.• Reduces brain inflammation, addressing a major factor in Parkinson’s disease progression• Earned FDA has Fast-Tracked Phase 1 and Phase 2 for both our cancer studies• Increases White Blood Cells (WBC) & Neutrophils (NEUT)*(WBC & NEUT are part of the cancer-fighting immune system - see image below)Our treatments set a new standard by prioritizing safety and effectiveness, tackling diseases at their root cause rather than merely alleviating symptomsWhile current treatment options for some diseases can cause devastating side effects and possibly damage internal organs and healthy cells, particularly with cancer drugs, other disease states like Parkinson's and ARDS are limited to treatments only relieving symptoms.Our drug changes that. It targets the underlying cause of these diseases, protecting organs and healthy cells from being damaged. We aim to offer safe and targeted treatments in places where they are not currently available.Our drug has been proven to be safe in early studiesThe Phase I Study has been completed, establishing the safety validity of our drug. We are now in Phase II in 3 of our clinical studies.These deadly diseases are widespread, with many untapped markets clear of competitionCurrently, the only medicines available for indications (medical conditions) like ARDS and Parkinson’s are symptom-treating drugs. We would control large sectors of the market void of completion with our targeted disease-focused treatments.Qualifications:Phase 3: 0 clinical trials (all companies have zero trials in Phase 3).Phase 2: 2 or 3 clinical trials (PhorMed has the advantage with 3 clinical trials at this stage compared to others with only 2).Phase 1 & Pre-Clinical: All have additional clinical trials and studies in development.With projected market values ranging between $290M-$1.2B, PhorMed has remarkable growth potential at just $53 million. Invest now and grow with the company.

## FAQ
1. **With the Common Stock will we receive annually dividends?**
   - Adan, thanks for your question. This offering does not include dividends..
2. **Hi Ben , I have already invested in your company through start engine. 2years back. At that time also your valuation was the same as of today. Why?? Why are you raising funds at same valuation? It is nothing but dilution of shares through unfair practices. Are you people at al...**
   - Arghya, apologies for the delayed response. Since your purchase the stock prices remain the same so no losses to your investment. The company is hitting milestones and stock price increases happen shortly after. Stand-by for those announcements.
3. **Mr Ben any courage to give any answer???**
   - Arghya, please see my response above.
4. **How many shares will my $250 investment secure?**
   - Larry, thank you for your question. Currently, we are running an early bird special, discounting the share price by 10% from $1.00 to $0.90. A $250 investment will get you 277 shares.
5. **When is this funding round closing?**
   - Douglas, thank you for your question. We expect to close this round in mid-April 2025.

## Team
- Ben Chang (CEO/Director)
- Prof. Richard L. Chang (Inventor/CSO)
- Carole A. Salvador, Psy.D (Secretary/Treasurer/HR Director)
- Sean M. O'Connell, Ph.D (CCO)
- Joseph Huffman (Finance Director)
- Julian Cepeda (Head of Operations)
- Xiaoxin Luke Chen (Advisory Board)
- Professor Renping Zhou (Advisory Board)
- Professor Xi Zheng (Advisory Board)
- Professor Harold H. Lee (Advisory Board)

## Q&A
- Q: Hi Ben , I have already invested in your company through start engine. 2years back. At that time also your valuation was the same as of today. Why?? Why are you raising funds at same valuation? It is nothing but dilution of shares through unfair practices. Are you people at all doing some serious business or planning to just raise funds and close the business after the fund raising?? answer...
  - A: Arghya, apologies for the delayed response. Since your purchase the stock prices remain the same so no losses to your investment. The company is hitting milestones and stock price increases happen shortly after. Stand-by for those announcements.
- Q: How many shares will my $250 investment secure?
  - A: Larry, thank you for your question. Currently, we are running an early bird special, discounting the share price by 10% from $1.00 to $0.90. A $250 investment will get you 277 shares.
- Q: Mr . Ben. I know that you are reading my questions but no courage to answer.Update your recent clinical trial progress. And what is the time line you have set to launch your first product in the market and investor exit plan too.
- Q: With the Common Stock will we receive annually dividends?
  - A: Adan, thanks for your question. This offering does not include dividends..
- Q: No major improvement seen in this company since last 5 years. Only raising funds. Does it have any business at all or planning to go away with money. Seriously I have doubt on their business and compliance. They are just changing the fund raising platforms. No major business or company valuation increase. Mr ben do you have any guts to answer?
- Q: Why is there no new news on your website and search engines since 2024, and your email address doesn't work as listed on your site?
- Q: With respect to your target of Hodgkin’s Lymphoma, my understanding is that 5-year progression free survival with existing treatments, especially N+AVD (with Nivolumab as the immunotherapy drug) is already around 90% with most patients making full recovery without the need for radiation. How would your compound improve on the outcome for patients from existing therapies?
  - A: Bernardo, thank you for your question! For Hodgkin's Lymphoma, our target population is relapsed/refractory patients, meaning patients whose cancer either resisted treatment or returned after first getting better. You can find this info in our "Solution" section of our pitch
- Q: Thanks for clarifying. I searched for your phase 2 studies in FDAs database but could not locate them. Can you please provide a link? My querry: https://clinicaltrials.gov/search?cond=Aml&aggFilters=phase:2&sort=StudyFirstPostDate
- Q: Mr Ben any courage to give any answer???
  - A: Arghya, please see my response above.
- Q: I thinks it's time for an update. Please share the latest news, either good or bad.
- Q: What is the exit plan (acquisition, IPO, merger, etc.) in which investors will be able to see a ROI?
- Q: Hi, considring your cooperation with overseas labs, are the recent policies on imported drugs going to affect your business plan and how much?
  - A: Hi Mirko, thanks for your question! It does not affect us at this point. We have enough inventory on hand for the next couple of years.
- Q: What is the current revenue?
  - A: Hi Yaacov, thanks for your question! We are currently pre-revenue and in drug development/clinical studies.
- Q: Can you elborate on the study design for your phase 2 studies? (How many patients, how long study time etc…)
  - A: Mads, thank you for your question! The study design is an open-label Phase 2 trial with 35 patients, requiring 20% efficiency (Fast-tracked status). Each treatment cycle lasts approximately 2-3 months, and the overall trial duration is expected to be around 24-30 months. Let me know if you have further questions or need additional details!
- Q: Can you speak more directly about your IP? I couldn't find it on your website (also your financials are nearly 3 years out of date). They photo caption in the overview says you received patents in 2019 and 2020. Are those owned by the company or licensed from Dr. Chang (and under what terms)? Should we assume that is the total of the IP? Are there other patents? If so, what? Is the viability of a final product predicated on any other IP/patents that you do not directly control and would need to license?
  - A: Lance, thanks for your question regarding our IP. All of our indications within our pipeline are on the list of our IP and are all patent-protected. All are assigned, not licensed, from Prof. Richard L. Chang, so we have full ownership and rights and are not reliant on any other third parties. If and when we have IP expansion, we will add them to our pipeline, and updates and press releases will be made.